Semaglutide (GLP-S) (Research Use Only)

Chemical Name: Semaglutide

Molecular Weight: 4113.64 g/mol

Sequence: H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-(AEEAc-AEEAc-Gamma-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

Appearance: White to off-white lyophilized powder

Storage: Store at −20°C

Form: Lyophilized powder; soluble in DMSO (3 mg/mL, 0.73 mM)

Description

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist extensively researched for its glucose-dependent insulin secretagogue activity and appetite suppression. It displays extended half-life due to structural modifications, making it suitable for once-weekly dosing studies. Semaglutide significantly improves glycemic control and promotes weight loss in metabolic disorder models.
(Wikipedia)
(DrugBank)

Research Applications

Investigation of glycemic regulation in Type 2 diabetes mellitus (T2DM) models
Study of appetite suppression and obesity-related weight loss
Pharmacokinetic and pharmacodynamic profiling for long-acting peptides
Evaluation of cardiovascular risk factor modulation
Preclinical and clinical efficacy and safety studies

Key Studies & Resources

Mechanism of Action

Semaglutide activates GLP-1 receptors, potentiating glucose-dependent insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing appetite signals. These effects culminate in improved glucose control and weight reduction observed in experimental models.
(DrugBank)

Safety and Handling

Store the lyophilized Semaglutide peptide at −20°C. Reconstitute immediately prior to laboratory use. Common mild adverse effects observed include gastrointestinal discomfort and transient injection site reactions in research models.

Disclaimer

For laboratory research use only. Not for human, medical, veterinary, or diagnostic application. This information is provided for scientific, research, and educational purposes only.